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Why was the cohort set up? 
The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) Study was initiated in 
2013 as the first large-scale study to assess clinical outcomes of people living with HIV (PLWH) over 
the age of 50 in England and Ireland.  Discussions around the management of HIV as a chronic 
disease have been ongoing (1-5).  However, some recent studies have suggested a possible 
acceleration of the aging process in PLWH with reported increases in the rates of several co-
morbidities, including cardiovascular disease (CVD), cancers, cognitive disorders, end-stage liver and 
renal disease and frailty and fracture risk (6-10). The primary aims of the study were therefore: (i) to 
describe the burden of clinical conditions in older PLWH; ii) to investigate whether the burden of co-
morbidities is increased in PLWH compared to demographically similar HIV-negative people; and iii) 
to describe the outcomes of and resources required to treat some of the more common co-
morbidities that were expected to occur in older PLWH to see whether these also appeared to differ 
between those with and without HIV.  An additional, related, aim of the study is to investigate the 
impact of age on the concentrations of the different antiretroviral agents in the blood among PLWH.  
It is hoped that the study findings will contribute to the development and implementation of 
evidence-based recommendations for the optimal management and clinical monitoring of older 
PLWH.  Study results will also contribute to the design of future studies for the treatment of diseases 
associated with ageing in this population. 
Funding and ethical approval 
This work is supported by various sources, including investigator initiated grants from several 
industry sources (Gilead Sciences, ViiV Healthcare, Bristol-Myers Squibb, Janssen-Cilag and Merck 
Sharp and Dohme), funding from the UK National Institute of Health Research (NIHR) through a 
Senior Investigator Award to Professor Sabin (grant no.531482 D-OTH 170963), funding from the 
Biomedical Research Council (BRC) at Imperial College London to Professor Winston and via Clinical 
Research Network (CRN) support at National Health Service sites in England.  None of the sponsors 
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(industry or otherwise) have any influence on the study design, the interpretation of study findings 
nor on the decision to present study findings.  In addition, several POPPY sub-studies have been 
funded through grants awarded by the British HIV Association (BHIVA), University College London, 
and Glaxo SmithKline to study investigators.  The study received ethical approval from the NHS 
Health Research Authority, National Research Ethics Service (NRES) Committee London. Ethics 
reference number: 12/LO/1409. POPPY has been registered with clinicaltrias.gov: 
https://clinicaltrials.gov/ct2/show/NCT01737047. 
Who is in the cohort? 
POPPY is a multicentre, prospective, observational study initially funded for three study visits which 
occur annually.  To address the primary aims of the study, three groups of individuals were invited to 
participate in the study: PLWH aged >50 years; PLWH aged <50 years; and a group of HIV-negative 
controls aged >50 years.   All participants were of white or black African ethnicity and had acquired 
HIV via a sexual route (either sex between men or sex between men and women).  Those recruited 
in the younger group of PLWH were frequency-matched to the group of older PLWH on gender, 
ethnicity, sexual orientation and participating clinic.  HIV-negative participants were required to 
have a documented negative HIV test in the past 6 months or at the time of screening; this group 
was frequency matched to the older PLWH group on age, gender, ethnicity, sexual orientation and 
geographical location (in or out of London).    
Eight clinical sites currently participate in POPPY: Chelsea and Westminster Hospital (CWH), 
Homerton University Hospital (HUH), Kings College Hospital (KCH), Mortimer Market Clinic (MMC), 
Royal Free Hospital (RFH), Royal Sussex County Hospital (RSH) and St Marys Hospital London (SMH) 
in England, and the Mater Misericordiae University Hospital, Dublin (DUH) in Ireland.  Prior to 
recruitment, each centre was provided with recruitment targets (for age group, gender, race and 
route of HIV infection) based on the demographic characteristics of those attending each clinic 
(using data from the UK Collaborative HIV Cohort (UK CHIC) Study (11) and the Dublin ID cohort (12) 
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to ensure that PLWH who participated in the study were broadly representative of PLWH in 
participating centres.  The number of people to be recruited from each centre was agreed in 
advance with study investigators and was based on an agreed proportion of the total numbers of 
attendees at each clinic to ensure feasibility.  
Identifying potential eligible participants and recruitment 
Our goal was to recruit a study cohort that did not over-represent those who either attended clinic 
more frequently or who were more regular participants in research studies.  To attempt to achieve 
this, each clinic’s list of eligible attendees was ordered randomly and clinics were asked to approach 
those at the top of the list first, before moving further down the list should insufficient numbers at 
the top of the list agree to participate.  Whilst not a perfect approach, this was felt to be a 
recruitment method that would be feasible within a busy clinic setting.   
Where possible, HIV-negative participants were selected from similar underlying populations (e.g. 
from genitourinary medicine clinics for the white men who have sex with men participants, and local 
community settings for those of black African origin).    
The original planned sample size was 2000 (1000 older PLWH, 500 younger PLWH and 500 HIV-
negative controls) and was chosen pragmatically to reflect what was felt to be feasible given the 
number of people receiving care at each of the clinics.  Given time constraints, however, recruitment 
was stopped once 1376 participants had been recruited (699 older PLWH, 374 younger PLWH and 
304 HIV-negative controls) as it was felt that the additional effort that would be required to increase 
the sample size further would not be balanced by an increased amount of information in the cohort. 
Characteristics of cohort 
The total cohort includes 1377 participants. Baseline demographic, clinical and lifestyle 
characteristics are shown in Table 1.  In brief, 1109 (80.5%) of the cohort were male (88.0%, 80.8% 
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and 64.0% in older PLWH, younger PLWH and HIV-negative controls, respectively), 963 (70.0%) 
defined themselves as men who have sex with men (MSM) and 1175 (85.3%) had a white ethnic 
background. The median age was 56 (Q1-Q3: 53-62) for the older PLWH, 43 (37-47) for the younger 
PLWH and 58 (53-63) for the HIV negative controls and almost 45% were single (54.0%, 31.0% and 
15.0%, respectively). Finally, around two-thirds (64.7%) of participants are born to parents from the 
UK/Ireland. 
[Table 1 here] 
To assess the representativeness of the older cohort (the younger cohort of PLWH was selected to 
be demographically similar to the older cohort, rather than to be representative of the UK HIV 
epidemic), we compared selected characteristics of the older cohort of PLWH within the UK POPPY 
sites (n=667/699) to individuals attending the same clinics who would have been eligible for 
participation in the study (based on age, ethnicity and exposure group) at the start of 2013, but who 
were not included (n=4786, Table 2).  Information for the latter group was obtained from the UK 
CHIC study.  Individuals who were included in POPPY were slightly more likely to be male (88.0% vs. 
85.4%), were more likely to report HIV infection through sex between men (79.8% vs. 70.4%) and to 
be of white ethnicity (86.4% vs. 79.5%) than non-participating individuals.  The median age of the 
two groups was, however, similar (55 vs. 54 years) as were the proportions of individuals exposed to 
ART (90.9% vs. 89.6%) and the median CD4 count on 1st January 2013 (590 cells/mm3 in each group).  
Absolute differences in the viral load and nadir CD4 cell count between the two groups were small.   
[Table 2 here] 
How often have they been followed up?    
The current protocol entails the following study visits:  a screening visit/Visit 1 (baseline) conducted 
from April 2013 until January 2016, during which eligibility criteria were confirmed and informed 
consent was taken; visit 2 (year 1) from May 2014 to February 2017; and visit 3 (year 2) from May 
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2015 to February 2018 (ongoing). Whilst the baseline and year 2 visits are conducted via face-to-face 
interviews for all participants, the intervening year 1 visit is only conducted face-to-face for the two 
groups of PLWH; the HIV-negative controls were contacted by phone for a brief follow-up 
assessment.  Current funding applications are under consideration to allow additional follow-up 
visits of the cohort. 
At the time of writing this manuscript (August 2017), 1315 (95.5%) of the cohort have reached visit 
2, and 508 (36.9%) have reached visit 3.  Eleven of the study participants have died, 10 from the 
older group of PLWH and 1 from the HIV-negative cohort.  Causes of death were: endocarditis, 
sepsis, ischemic and hypertrophic heart disease, myocardial infraction, adenocarcinoma, suicide, 
heart attack, cardiac arrest, end-stage liver disease and angiosarcoma.  Thirty-two participants have 
withdrawn further participation, 17 from the older HIV-positive, 11 from the younger HIV-positive 
and 4 from the HIV-negative group. The Imperial College Clinical Trials Unit (ICTU) makes efforts to 
retain a low attrition rate. 
What has been measured? 
A detailed schematic showing the information collected at each visit is shown in Box 1.   At the 
baseline and year 2 visit, information is collected on demographics, socio-economic status, 
anthropometrics and lifestyle factors.  A full clinical history is taken by trained clinical research staff, 
with a particular focus on any co-morbidities or clinical conditions that are present, any medications 
that have been received and any healthcare resources that have been used over the past year.  
Information on family history of clinical conditions is collected along with current and historic use of 
antiretroviral medication, for both the older and younger PLWH. Gender-specific information has 
been collected for pregnancies and screening for cervical and breast cancer for women and anal 
cancer screening for men.  Cognitive function is assessed at baseline and year 2 using specific 
memory and cognitive testing assessing cortical and sub-cortical function and a detailed pain 
assessment reports regional and widespread pain using a validated mannequin.  A full dual x-ray 
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absorptiometry (DXA) scan is performed at baseline and year 2.  Local scanners are used for 
measuring bone mineral density (BMD) to evaluate bone health and determine the likelihood of 
osteoporosis or bone fractures.  To supplement this, information is also captured on any falls that 
the participant has experienced over the previous year, and on factors that will permit an 
assessment of falls and frailty risk. 
[Box 1 here] 
Blood (serum, plasma, and peripheral blood mononuclear cells (PBMC)) are taken for storage and for 
pharmacokinetic analysis at baseline and year 2; it is planned that these will be used for subsequent 
projects of the potential pathogenic mechanisms underlying age-related diseases. Plasma of 4-5 mL 
blood in ethylenediaminetetraacetic acid (EDTA) or lithium heparin has been collected for 
pharmacokinetic analysis, including but not limited to antiretroviral drug exposure and drug-drug 
interaction (DDI) of concomitant medication. For each participant record of sample time and time of 
food intake nearest to the last dose prior to sampling and food content was recorded. PLWH also 
reported the time of last ART dose. Other samples collected include 3X6 mL of plasma in EDTA, 15 
mL of serum and approximately 5 mL of urine. 
Linkage to historical longitudinal HIV data 
For participants at the UK sites, data linkage is performed with the UK CHIC Study to provide access 
to historical longitudinal data on ART, hepatitis B virus (HBV) and hepatitis C virus (HCV) status and 
laboratory data including CD4 counts and percentages, CD8 counts and percentages and 
assessments of HIV RNA (11).  For participants at the Dublin site, historical longitudinal data were 
available through linkage with the Dublin ID cohort, which includes all patients diagnosed with HIV 
and seen for care at the Mater Misericordiae University Hospital in Dublin from 1993 to 1st 
December 2014.  
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What has been found?  Key findings and publications 
Given the broad-subject information collected through POPPY study, a long list of projects are 
involved, investigating the association of aging with several co-morbidities. Future ongoing and 
planned projects will involve studies of: sleeping patterns, muscle biopsy, pharmacokinetic and DDIs, 
cerebrovascular and cardiovascular disease, cognitive analysis, the menopause in women living with 
HIV, hepatic steatosis, respiratory events, bone health and fractures, mental health, and chronic 
pain.  
A recent project within POPPY investigated the agreement of different approaches used to define 
cognitive impairment in HIV (13). The Frascati criteria, global deficit score (GDS) and multivariate 
normative comparison (MNC) were used to define cognitive impairment. We found that the 
different criteria of cognitive impairment show fair diagnostic agreement in PLWH and that those 
meeting all three criteria had the highest rates of symptomatology. In another POPPY publication, 
Underwood et al. (14) found weak associations between the same three criteria of cognitive 
impairment and patient-reported measures of physical/mental functioning in older PLWH.  
What are the main strengths and weaknesses? 
Currently, there is no large study on HIV and the effects of ageing in the UK and Ireland. 
Internationally, several research groups have developed initiatives in this area, but most of these 
studies are either limited by size, or are still at the recruitment stage. POPPY is a large multicentre 
cohort and is representative of the HIV-positive population in the UK and Ireland that achieved a 
remarkable enrolment of almost 1400 participants. The inclusion of an older HIV-positive group, a 
younger HIV-positive group and an appropriately-selected older control group in the study allows for 
direct comparisons of the clinical outcomes between the older HIV-positive and HIV-negative groups 
and the inclusion of the younger HIV-positive group elucidates the effect of age within the HIV 
participants.  
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The data linkage of POPPY with a well-established Irish HIV centre and centres that are already 
participating in the UK CHIC cohort, enabled the enhancement of the quality of the data and allowed 
access to HIV-specific historical data of the POPPY participants, minimising the resources that are 
required to collect historic longitudinal HIV data. The cohort will be of help in determining a wide 
range of data over time, related to clinical outcomes and HIV and ageing that will facilitate research 
that involves long-term follow-up. POPPY study is an important cohort for those investigating the 
mechanism of HIV and ageing, clinical conditions and impact of antiretroviral treatment in Ireland 
and UK.  
A limitation of the POPPY study is the lack of a young HIV-negative group that would facilitate a 
direct comparison with the younger group of PLWH, and an over-representation of white women 
among the HIV-negative control group. Due to time and budget constrains this was not feasible. 
Future studies should consider incorporating such a group in their design in order to understand 
patterns and behaviours as well as similarities and differences with younger PLWH.  
Can I get hold of the data? Where can I find out more?  
Further information for the cohort collaboration policy can be obtained from Professor Caroline 
Sabin [c.sabin@ucl.ac.uk] and Professor Alan Winston [a.winston@imperial.ac.uk]. 
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Key messages: 
• POPPY is the first large-scale study of people living with HIV (PLWH) over the age of 50 in 
England and Ireland. 
• This cohort represents a unique opportunity to investigate whether HIV is a shortcut to 
ageing.  
• An appropriately-selected control group enables a direct comparisons of the clinical 
outcomes between the older HIV-positive and HIV-negative group. 
• More than 95% of the 1377 participants completed a follow up visit. 
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Profile in a nutshell 
The POPPY Study is the first large-scale study to assess clinical outcomes of people living with HIV 
(PLWH) over the age of 50 in England and Ireland.   
PLWH aged >50 years (n=699), PLWH aged <50 years (n=374) and HIV-negative people aged >50 
years (n=304), frequency-matched for demographics and lifestyle, were recruited from eight sites in 
the UK and Ireland.  Study visits started in April 2013.  The cohort is largely male (80.5%), men who 
have sex with men (MSM) (70.0%) and of white ethnicity (85.3%).  The median age was 56 (first 
quartile - third quartile: 53-62), 43 (37-48) and 58 (54-63) in the three groups, respectively. 
Participants are seen annually; 586 of the cohort have attended all three currently funded visits, 11 
participants have died and 32 have been lost to follow-up.   
Information is collected on demographics, socio-economic status, anthropometrics and lifestyle 
factors.  A clinical history is taken, and information is collected on medications and healthcare 
resources that have been used over the past year.  Cognitive function, bone health and pain are 
assessed, and blood samples are stored. Data linkage is performed with two HIV cohort studies to 
provide access to historical longitudinal HIV data. 
Further information can be obtained from Prof Caroline Sabin [c.sabin@ucl.ac.uk] and Prof Alan 
Winston [a.winston@imperial.ac.uk]. 
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